IL-6 is a promising target, but many of the studies involving IL-6 antibodies have been in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (Rigas et al., 2010; Schuster et al., 2010; Bayliss et al., 2011; Ando et al., 2013). This evidence concerns the gene IL6 and non-small cell lung carcinoma.